Furthermore, an estimated 33.6% of NSCLC patients with EGFR-mutant tumors received erlotinib, which was also administered to 5.9% of NSCLC patients with EGFR-wild type tumors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.